HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Leu, L. Articles by Mohassel, L. PubMed PubMed Citation Articles by Leu, L. Articles by Mohassel, L.

LILY LEU, PHARM.D., is Postgraduate Year 1 Pharmacy Resident; and LEILA MOHASSEL, PHARMD., BCPS, is Pharmacy Clinical Specialist— . Hematology/Oncology, Department of Pharmacy, Inova Fairfax Hospital, Falls Church, VA.

Address correspondence to Dr. Mohassel at the Department of Pharmacy, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042 (leila.mohassel{at}inova.org).

Purpose. The history, clinical pharmacology and toxicities, and role of arsenic trioxide as a first-line agent for treating acute promyelocytic leukemia (APL) are described. Summary. APL is most often characterized by the hallmark reciprocal translocation between chromosomes 15 and 17, leading to the fusion of the promyelocytic gene and retinoic acid receptor . Arsenic’s therapeutic utility as an antileukemic agent was first described in the late 18th century. Arsenic trioxide demonstrates a dual, dose-dependent mechanism of action and can induce both partial myeloid differentiation and apoptosis. Arsenic trioxide is generally well tolerated, with reversible toxicities rarely requiring discontinuation of therapy. Toxicities associated with arsenic trioxide include leukocytosis, Q-T interval prolongation, APL differentiation syndrome, and hepatotoxicity. Since 2000, arsenic trioxide has been used as the standard of care for relapsed APL, with remission rates greater than 80% as a single agent. In an attempt to maximize disease-free survival and minimize relapse rates in patients with APL, arsenic trioxide is now being investigated as first-line therapy in the management of APL, with several studies showing promising outcomes. When used alone or in combination with tretinoin, the rates of complete remission have exceeded 85%, with high rates of molecular remission. Conclusion. Arsenic trioxide, alone or in combination with tretinoin, as first-line therapy in newly diagnosed APL has resulted in high rates of complete remission and molecular remission. Arsenic trioxide combined with tretinoin has shortened the time to achieve complete remission and lengthened disease-free survival, findings that suggest the usefulness of the regimen as first-line treatment for APL. Index terms: Antineoplastic agents; Arsenic trioxide; Combined therapy; Dosage; History; Leukemia; Mechanism of action; Toxicity; Tretinoin